Literature DB >> 17922323

Thalamic deep brain stimulation in the treatment of essential tremor: a long-term follow-up.

P Blomstedt1, G-M Hariz, M I Hariz, L-O D Koskinen.   

Abstract

Deep brain stimulation (DBS) of the nucleus ventralis intermedius thalami (Vim) in the treatment of essential tremor (ET) is well documented concerning the acute effects. Reports of the long-term effects are, however, few and the aim of the present study was to analyse the long-term efficacy of this treatment. Nineteen patients operated with unilateral Vim-DBS were evaluated with the Essential Tremor Rating Scale (ETRS) before surgery, and after a mean time of 1 and 7 years after surgery. The ETRS score for tremor of the contralateral hand was reduced from 6.8 at baseline to 1.2 and 2.7, respectively, on stimulation at follow-up. For hand function (item 11 - 14) the score was reduced from 12.7 to 4.1 and 8.2, respectively. Vim-DBS is an efficient treatment for ET, also after many years of treatment. There is, however, a decreasing effect over time, most noticeable concerning tremor of action.

Entities:  

Mesh:

Year:  2007        PMID: 17922323     DOI: 10.1080/02688690701552278

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  44 in total

1.  Improved spatial targeting with directionally segmented deep brain stimulation leads for treating essential tremor.

Authors:  Maureen Keane; Steve Deyo; Aviva Abosch; Jawad A Bajwa; Matthew D Johnson
Journal:  J Neural Eng       Date:  2012-06-25       Impact factor: 5.379

Review 2.  [Deep brain stimulation for hyperkinetic movement disorders].

Authors:  M M Reich; J Volkmann
Journal:  Nervenarzt       Date:  2014-02       Impact factor: 1.214

3.  A patient with tremor, part 2: from diagnosis to treatment.

Authors:  Hrishikesh Kumar; Mandar Jog
Journal:  CMAJ       Date:  2011-08-15       Impact factor: 8.262

Review 4.  Directional Deep Brain Stimulation.

Authors:  Frank Steigerwald; Cordula Matthies; Jens Volkmann
Journal:  Neurotherapeutics       Date:  2019-01       Impact factor: 7.620

5.  Update on treatment of essential tremor.

Authors:  Theresa A Zesiewicz; Jessica D Shaw; Kevin G Allison; Joseph S Staffetti; Michael S Okun; Kelly L Sullivan
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

6.  Diffusion tractography imaging-guided frameless linear accelerator stereotactic radiosurgical thalamotomy for tremor: case report.

Authors:  Won Kim; Justin Sharim; Stephen Tenn; Tania Kaprealian; Yvette Bordelon; Nzhde Agazaryan; Nader Pouratian
Journal:  J Neurosurg       Date:  2017-02-24       Impact factor: 5.115

7.  Objective predictors of 'early tolerance' to ventral intermediate nucleus of thalamus deep brain stimulation in essential tremor patients.

Authors:  Shabbir Hussain Merchant; Sheng-Han Kuo; Yu Qiping; Linda Winfield; Guy McKhann; Sameer Sheth; Seth L Pullman; Blair Ford
Journal:  Clin Neurophysiol       Date:  2018-06-05       Impact factor: 3.708

Review 8.  Disease-specific longevity of impulse generators in deep brain stimulation and review of the literature.

Authors:  Christoph van Riesen; Georg Tsironis; Doreen Gruber; Fabian Klostermann; Patricia Krause; Gerd Helge Schneider; Andreas Kupsch
Journal:  J Neural Transm (Vienna)       Date:  2016-05-19       Impact factor: 3.575

Review 9.  Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association.

Authors:  Mario Zappia; Alberto Albanese; Elisa Bruno; Carlo Colosimo; Graziella Filippini; Paolo Martinelli; Alessandra Nicoletti; Graziella Quattrocchi; Giovanni Abbruzzese; Alfredo Berardelli; Roberta Allegra; Maria Stella Aniello; Antonio E Elia; Davide Martino; Daniela Murgia; Marina Picillo; Giovanna Squintani
Journal:  J Neurol       Date:  2012-08-11       Impact factor: 4.849

Review 10.  Deep Brain Stimulation in Neurological and Psychiatric Disorders.

Authors:  Volker A Coenen; Florian Amtage; Jens Volkmann; Thomas E Schläpfer
Journal:  Dtsch Arztebl Int       Date:  2015-08-03       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.